Literature DB >> 6096752

Effects of alpha-flupenthixol and naloxone on CRF-induced locomotor activation.

G F Koob, N Swerdlow, M Seeligson, M Eaves, R Sutton, J Rivier, W Vale.   

Abstract

Corticotropin-releasing factor injected intracerebroventricularly in a dose of 1 microgram produced a prolonged locomotor activation (3 h) in rats previously habituated to the test cage environment. This activation was reversed by alpha-flupenthixol (intraperitoneally), a dopamine receptor antagonist, only at cataleptic doses and not at all by naloxone (subcutaneously) in doses of 0.02-5.0 mg/kg. The effective dose 50% (ED50) for the alpha-flupenthixol reversal of locomotor activity induced by corticotropin-releasing factor was 0.13 mg/kg; similar to the 0.14 mg/kg ED50 needed to reverse the locomotor activation produced by caffeine (10 mg/kg s.c.). The ED50 necessary to reverse amphetamine (0.75 mg/kg s.c.) locomotion with this drug was 0.07 mg/kg. The results suggest that the corticotropin-releasing factor acts independently of direct activation of the dopamine or opioid peptide systems.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6096752     DOI: 10.1159/000124021

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  10 in total

1.  Corticotropin-releasing factor in the norepinephrine nucleus, locus coeruleus, facilitates behavioral flexibility.

Authors:  Kevin Snyder; Wei-Wen Wang; Rebecca Han; Kile McFadden; Rita J Valentino
Journal:  Neuropsychopharmacology       Date:  2011-10-12       Impact factor: 7.853

2.  Impaired diurnal adrenal rhythmicity restored by constant infusion of corticotropin-releasing hormone in corticotropin-releasing hormone-deficient mice.

Authors:  L J Muglia; L Jacobson; S C Weninger; C E Luedke; D S Bae; K H Jeong; J A Majzoub
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

Review 3.  Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.

Authors:  Glenn R Valdez
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Neuropeptide modulation of central amygdala neuroplasticity is a key mediator of alcohol dependence.

Authors:  Nicholas W Gilpin; Marisa Roberto
Journal:  Neurosci Biobehav Rev       Date:  2011-11-11       Impact factor: 8.989

5.  Low doses of corticotropin-releasing factor potentiate amphetamine-induced stereotyped behavior.

Authors:  B J Cole; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Corticotropin releasing factor induces anxiogenic locomotion in trout and alters serotonergic and dopaminergic activity.

Authors:  Russ E Carpenter; Michael J Watt; Gina L Forster; Øyvind Øverli; Craig Bockholt; Kenneth J Renner; Cliff H Summers
Journal:  Horm Behav       Date:  2007-08-08       Impact factor: 3.587

7.  Differential blockade of CRF-evoked behaviors by depletion of norepinephrine and serotonin in rats.

Authors:  Owen Howard; Gregory V Carr; Tiffany E Hill; Rita J Valentino; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2008-05-31       Impact factor: 4.530

Review 8.  Corticotropin-releasing factor (CRF) and neuropeptide Y (NPY): effects on inhibitory transmission in central amygdala, and anxiety- & alcohol-related behaviors.

Authors:  Nicholas W Gilpin
Journal:  Alcohol       Date:  2012-05-04       Impact factor: 2.405

9.  Nucleus accumbens corticotropin-releasing factor increases cue-triggered motivation for sucrose reward: paradoxical positive incentive effects in stress?

Authors:  Susana Peciña; Jay Schulkin; Kent C Berridge
Journal:  BMC Biol       Date:  2006-04-13       Impact factor: 7.431

Review 10.  The CRF Family of Neuropeptides and their Receptors - Mediators of the Central Stress Response.

Authors:  Nina Dedic; Alon Chen; Jan M Deussing
Journal:  Curr Mol Pharmacol       Date:  2018       Impact factor: 3.339

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.